{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:39:57Z","timestamp":1780407597012,"version":"3.54.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Appropriate dosing of piperacillin\/tazobactam is crucial for hospitalized children and might be a challenge in case of augmented renal clearance. This study assessed the appropriateness of piperacillin dosing regimens recommended to attain pharmacokinetic\/pharmacodynamic targets by pediatric guidelines using a population pharmacokinetic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A population pharmacokinetic model for piperacillin was developed using therapeutic drug monitoring observations collected in hospitalized children between 2012 and 2021. Subsequently, simulations were performed to evaluate whether dosing regimens recommended by various pediatric guidelines achieved the pharmacodynamic target [i.e. maintaining free piperacillin plasma concentrations above the minimum inhibitory concentration for 100% of the dosing interval (100% fT\u200a&amp;gt;\u200aMIC)] in case of augmented, normal and moderately impaired renal functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The model best describing our 386 concentration values in 104 patients was a two-compartment model with allometric scaling of pharmacokinetic parameters based on bodyweight. Renal function also influenced clearance. Simulations revealed a risk of underdosing in patients with a creatinine clearance above 50\u2005mL\/min\/1.73\u2005m2 when piperacillin was administered as intermittent infusions, according to most guidelines. In contrast, continuous infusions consistently achieved the pharmacodynamic target even for MIC close to the limit of susceptibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the critical impact of renal function on piperacillin pharmacokinetics in pediatric patients. Continuous infusion regimens are necessary to ensure optimal drug exposure and efficacy, particularly in patients with augmented creatinine clearance. These results emphasize the need to revise pediatric dosing strategies considering a broader range of renal function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf387","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:09:11Z","timestamp":1759320551000},"page":"3419-3430","source":"Crossref","is-referenced-by-count":1,"title":["Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage?"],"prefix":"10.1093","volume":"80","author":[{"given":"Anne","family":"Ravix","sequence":"first","affiliation":[{"name":"Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermindo Roberto","family":"Di Paolo","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Lausanne University Hospital , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-3435","authenticated-orcid":false,"given":"Kim","family":"Dao","sequence":"additional","affiliation":[{"name":"Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Helena","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Women Mother Child, Pediatric Intensive and Intermediate Care Units, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Alex","family":"Crisinel","sequence":"additional","affiliation":[{"name":"Department of Woman Mother and Child, Unit of Pediatric Infectious Diseases and Vaccinology, Service of Pediatrics, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-5536","authenticated-orcid":false,"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[{"name":"Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Marzolini","sequence":"additional","affiliation":[{"name":"Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel , Basel ,","place":["Switzerland"]},{"name":"Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-082X","authenticated-orcid":false,"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[{"name":"Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"School of Pharmaceutical Sciences, University of Geneva, University of Lausanne , Geneva ,","place":["Switzerland"]},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne , Geneva & Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-9317","authenticated-orcid":false,"given":"Monia","family":"Guidi","sequence":"additional","affiliation":[{"name":"Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne , Geneva & Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2025120206225140900_dkaf387-B1","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00467-019-04205-x","article-title":"Augmented renal clearance: a common condition in critically ill children","volume":"34","author":"Van Der Heggen","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2025120206225140900_dkaf387-B2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/phar.2617","article-title":"Scoping review of augmented renal clearance in critically ill pediatric patients","volume":"41","author":"Rhoney","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2025120206225140900_dkaf387-B3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/antibiotics9070393","article-title":"Augmented renal clearance and how to augment antibiotic dosing","volume":"9","author":"Chen","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025120206225140900_dkaf387-B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","article-title":"Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?","volume":"35","author":"Dhont","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"2025120206225140900_dkaf387-B5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: a systematic review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2025120206225140900_dkaf387-B6","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1097\/INF.0b013e318286c612","article-title":"The antibiotic resistance and prescribing in European children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide","volume":"32","author":"Versporten","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2025120206225140900_dkaf387-B7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1542\/peds.2010-1275","article-title":"Variability in antibiotic use at children's hospitals","volume":"126","author":"Gerber","year":"2010","journal-title":"Pediatrics"},{"key":"2025120206225140900_dkaf387-B8","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1086\/519256","article-title":"Optimizing drug exposure to minimize selection of antibiotic resistance","volume":"45","author":"Olofsson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025120206225140900_dkaf387-B9","doi-asserted-by":"publisher","first-page":"114006","DOI":"10.1016\/j.ijheh.2022.114006","article-title":"Prevalence of ESKAPE pathogens in the environment: antibiotic resistance status, community-acquired infection and risk to human health","volume":"244","author":"Denissen","year":"2022","journal-title":"Int J Hyg Environ Health"},{"key":"2025120206225140900_dkaf387-B10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmicb.2013.00020","article-title":"Concentration-dependent activity of antibiotics in natural environments","volume":"4","author":"Bernier","year":"2013","journal-title":"Front Microbiol"},{"key":"2025120206225140900_dkaf387-B11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/antibiotics10040393","article-title":"Antibiotic resistance in pediatric infections: global emerging threats, predicting the near future","volume":"10","author":"Romandini","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025120206225140900_dkaf387-B12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/CCM.0000000000002817","article-title":"\u03b2-lactam therapeutic drug management in the PICU","volume":"46","author":"Cies","year":"2018","journal-title":"Crit Care Med"},{"key":"2025120206225140900_dkaf387-B13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0732-8893(03)00112-3","article-title":"Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC program (2002) in North America","volume":"47","author":"Rhomberg","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025120206225140900_dkaf387-B14","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)"},{"key":"2025120206225140900_dkaf387-B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40560-020-00504-w","article-title":"The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome","volume":"8","author":"Scharf","year":"2020","journal-title":"J Intensive Care"},{"key":"2025120206225140900_dkaf387-B16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s40746-022-00259-6","article-title":"Optimization of pediatric antibiotic dosing through therapeutic drug monitoring","volume":"8","author":"Zhu","year":"2022","journal-title":"Curr Treat Options Pediatr"},{"key":"2025120206225140900_dkaf387-B17","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1093\/jac\/dkv201","article-title":"Therapeutic drug monitoring of the \u03b2-lactam antibiotics: what is the evidence and which patients should we be using it for?","volume":"70","author":"Huttner","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225140900_dkaf387-B18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American college of clinical pharmacy, British Society for Antimicrobial Chemotherapy, cystic fibrosis foundation, European society of clinical microbiology and infectious diseases, Infectious Diseases Society of America, society of critical care medicine, and society of infectious diseases pharmacists","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025120206225140900_dkaf387-B19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and intensive care medicine (soci\u00e9t\u00e9 fran\u00e7aise d\u2019Anesth\u00e9sie et r\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"2025120206225140900_dkaf387-B20","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of \u03b2-lactam concentration\u2013toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225140900_dkaf387-B21","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1097\/PCC.0000000000002951","article-title":"Suboptimal beta-lactam therapy in critically ill children: risk factors and outcome","volume":"23","author":"Van Der Heggen","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"2025120206225140900_dkaf387-B22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/antibiotics9030131","article-title":"Therapeutic drug monitoring of meropenem and piperacillin in critical illness\u2014experience and recommendations from one year in routine clinical practice","volume":"9","author":"Scharf","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025120206225140900_dkaf387-B23","doi-asserted-by":"publisher","first-page":"768438","DOI":"10.3389\/fped.2021.768438","article-title":"Ensuring sufficient trough plasma concentrations for broad-spectrum beta-lactam antibiotics in children with malignancies: beware of augmented renal clearance!","volume":"9","author":"Andr\u00e9","year":"2022","journal-title":"Front Pediatr"},{"key":"2025120206225140900_dkaf387-B24","doi-asserted-by":"publisher","first-page":"1254005","DOI":"10.3389\/fphar.2024.1254005","article-title":"Piperacillin\/tazobactam treatment in children: evidence of subtherapeutic concentrations","volume":"15","author":"Ye","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025120206225140900_dkaf387-B25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40272-020-00426-y","article-title":"Optimizing the use of antibiotic agents in the pediatric intensive care unit: a narrative review","volume":"23","author":"Willems","year":"2021","journal-title":"Paediatr Drugs"},{"key":"2025120206225140900_dkaf387-B26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/17425255.2024.2385403","article-title":"Dose optimization of \u03b2-lactam antibiotics in children: from population pharmacokinetics to individualized therapy","volume":"20","author":"Ngougni Pokem","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025120206225140900_dkaf387-B27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/archdischild-2017-314506","article-title":"Pharmacokinetic studies in children: recommendations for practice and research","volume":"103","author":"Barker","year":"2018","journal-title":"Arch Dis Child"},{"key":"2025120206225140900_dkaf387-B28","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/antibiotics10101182","article-title":"Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine","volume":"10","author":"Gijsen","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025120206225140900_dkaf387-B29","volume-title":"BNF for Children 2024","author":"Committee PF","year":"2024"},{"key":"2025120206225140900_dkaf387-B30","volume-title":"The Harriet Lane Handbook","author":"Anderson","year":"2024","edition":"23rd edn"},{"key":"2025120206225140900_dkaf387-B31","author":"Lexidrug"},{"key":"2025120206225140900_dkaf387-B32","author":"SwissPedDose"},{"key":"2025120206225140900_dkaf387-B33","doi-asserted-by":"crossref","DOI":"10.1542\/9781610025225","volume-title":"Red Book: 2021-2024 Report of the Committee on Infectious Diseases\/Committee on Infectious Diseases, American Academy of Pediatrics; David W. Kimberlin, editor; Elizabeth D. Barnett, associate editor; Ruth Lynfield, associate editor; Mark H. Sawyer, associate editor","author":"Kimberlin","year":"2021"},{"key":"2025120206225140900_dkaf387-B34","volume-title":"Nelson Textbook of Pediatrics","author":"Kliegman","year":"2011"},{"key":"2025120206225140900_dkaf387-B35","author":"Micromedex"},{"key":"2025120206225140900_dkaf387-B36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025120206225140900_dkaf387-B37","doi-asserted-by":"publisher","first-page":"122160","DOI":"10.1016\/j.jchromb.2020.122160","article-title":"Validation and clinical application of a multiplex high performance liquid chromatography\u2014tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections","volume":"1157","author":"Decosterd","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025120206225140900_dkaf387-B38","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci"},{"key":"2025120206225140900_dkaf387-B39","author":"PSN"},{"key":"2025120206225140900_dkaf387-B40","author":"Nebraska Medicine"},{"key":"2025120206225140900_dkaf387-B41","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/jac\/dkz270","article-title":"Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen","volume":"74","author":"Thorsted","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225140900_dkaf387-B42","doi-asserted-by":"publisher","first-page":"e01260-19","DOI":"10.1128\/AAC.01260-19","article-title":"Population pharmacokinetics and safety of piperacillin-tazobactam extended infusions in infants and children","volume":"63","author":"Thibault","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225140900_dkaf387-B43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/INF.0b013e3182a743c7","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children","volume":"33","author":"Cies","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2025120206225140900_dkaf387-B44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/pbc.25287","article-title":"Population pharmacokinetics of the piperacillin component of piperacillin\/tazobactam in pediatric oncology patients with fever and neutropenia","volume":"62","author":"Cies","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2025120206225140900_dkaf387-B45","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/jac\/dkx093","article-title":"Dose optimization of piperacillin\/tazobactam in critically ill children","volume":"72","author":"De Cock","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225140900_dkaf387-B46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40272-024-00664-4","article-title":"Population pharmacokinetics and dose optimization of piperacillin in infants and children with pneumonia","volume":"27","author":"Jirasomprasert","year":"2025","journal-title":"Paediatr Drugs"},{"key":"2025120206225140900_dkaf387-B47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40262-018-0682-1","article-title":"Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance","volume":"58","author":"B\u00e9ranger","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2025120206225140900_dkaf387-B48","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1128\/AAC.02089-15","article-title":"Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225140900_dkaf387-B49","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/ppul.26299","article-title":"Evaluation of the safety of piperacillin-tazobactam extended infusion in pediatric cystic fibrosis patients","volume":"58","author":"Riggsbee","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2025120206225140900_dkaf387-B50","doi-asserted-by":"publisher","first-page":"114220","DOI":"10.1016\/j.jpeds.2024.114220","article-title":"Prolonged beta-lactam infusions in children: a systematic review and meta-analysis","volume":"275","author":"Briand","year":"2024","journal-title":"J Pediatr"},{"key":"2025120206225140900_dkaf387-B51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/antibiotics13020164","article-title":"Extended infusion of beta-lactams and glycopeptides: a new era in pediatric care? A systematic review and meta-analysis","volume":"13","author":"Burch","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025120206225140900_dkaf387-B52","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.accpm.2024.101354","article-title":"Continuous infusion of beta-lactam antibiotics in pediatric intensive care unit: a monocenter before\/after implementation study","volume":"43","author":"Ragonnet","year":"2024","journal-title":"Anaesth Crit Care Pain Med"},{"key":"2025120206225140900_dkaf387-B53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025120206225140900_dkaf387-B54","doi-asserted-by":"publisher","first-page":"102293","DOI":"10.1016\/j.eclinm.2023.102293","article-title":"Extended infusion of \u03b2-lactams significantly reduces mortality and enhances microbiological eradication in paediatric patients: a systematic review and meta-analysis","volume":"65","author":"Budai","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025120206225140900_dkaf387-B55","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5863\/1551-6776-27.3.214","article-title":"A review of extended and continuous infusion beta-lactams in pediatric patients","volume":"27","author":"Imburgia","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2025120206225140900_dkaf387-B56","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/nicc.12754","article-title":"Compatibility of prolonged infusion antibiotics during Y-site administration","volume":"27","author":"Nunez-Nunez","year":"2022","journal-title":"Nurs Crit Care"},{"key":"2025120206225140900_dkaf387-B57","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.clinthera.2012.05.005","article-title":"System-wide implementation of the use of an extended-infusion piperacillin\/tazobactam dosing strategy: feasibility of utilization from a children's hospital perspective","volume":"34","author":"Nichols","year":"2012","journal-title":"Clin Ther"},{"key":"2025120206225140900_dkaf387-B58","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/1060028014566447","article-title":"Implementing extended-infusion cefepime as standard of care in a children\u2019s hospital: a prospective descriptive study","volume":"49","author":"Nichols","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2025120206225140900_dkaf387-B59","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/INF.0000000000004054","article-title":"Relationship between real-time TDM-guided pharmacodynamic target attainment of continuous infusion beta-lactam monotherapy and microbiologic outcome in the treatment of critically ill children with severe documented gram-negative infections","volume":"42","author":"Gatti","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"2025120206225140900_dkaf387-B60","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00467-010-1598-7","article-title":"Validation of the revised Schwartz estimating equation in a predominantly non-CKD population","volume":"25","author":"Staples","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"2025120206225140900_dkaf387-B61","author":"Warady"},{"key":"2025120206225140900_dkaf387-B62","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3390\/children9121995","article-title":"Glomerular filtration rate assessment in children","volume":"9","author":"Jan\u010di\u010d","year":"2022","journal-title":"Children (Basel)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3419\/65046595\/dkaf387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3419\/65046595\/dkaf387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:59Z","timestamp":1764674579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3419\/8307255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf387","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,31]]}}}